GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of Arexvy (Respiratory Syncytial Virus Vaccine) when co-administered with Shingrix (Zoster Vaccine).
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Findings showed a noninferior immune response for both vaccines when Shingrix and Arexvy were coadministered compared with separate administration (primary endpoint). Both anti-gE antibody concentrations (immune response to Shingrix) and RSV-A and RSV-B neutralization titers increased from pre- to post-vaccination.
GSK Shingles Vaccine in Malaysia: Here’s What You Need to Know
GSK has launched it's Shingles vaccine in Malaysia and here's all you need to know about it. From what it is, to the side effects, for whom and where to get it.
GSK shingles vaccine now available in Malaysia
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine, Shingrix (MAL24056002ARZ), also known as Recombinant Zoster Vaccine, Adjuvanted (RZV) in Malaysia for the prevention of shingles (herpes zoster,
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
Shingrix is approved to prevent shingles (herpes zoster) in adults aged 50 and older ... Also Read: GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like ...
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older. The British pharma giant said Wednesday a Phase 3 study evaluating RSV vaccine Arexvy co-administered with Shingrix met the primary endpoint,
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.
dermatologyadvisor11d
No Increased Risk for Incident Gout After RZV Exposure Among Adults Aged 50 Years or Older
The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.
health.economictimes.indiatimes18h
Voluntary vaccination among adults can significantly reduce lung infections incidence
It is important for vulnerable people and the elderly to stay up to date on vaccinations such as influenza (to protect ...
Armed robbery in Revesby3d
More Australians to Get Funded Shingles Vaccine
Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...
Medscape7d
Varicella and Varicella-Zoster Vaccine
The Advisory Committee on Immunization Practices (ACIP) recommends a single dose of zoster vaccine for immunocompetent adults 60 years of age and older, based on the results of this study ...
Renal & Urology News12d
No Increased Risk for Incident Gout After RZV Exposure Among Adults Aged 50+
Among the 461,323 individuals who received at least 1 RZV dose, 1264 experienced new-onset gout within 60 days postvaccination; 302 patients were determined to have incident cases of gout, with no ...
infectiousdiseaseadvisor.com12d
No Increased Risk for Incident Gout After RZV Exposure Among Adults Aged 50 Years and Older
The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.